Ameriprise Financial Inc. Trims Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Ameriprise Financial Inc. trimmed its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 41.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 125,630 shares of the biopharmaceutical company’s stock after selling 88,350 shares during the quarter. Ameriprise Financial Inc. owned approximately 0.21% of Sage Therapeutics worth $682,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. SG Americas Securities LLC increased its holdings in Sage Therapeutics by 57.7% in the fourth quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 8,228 shares in the last quarter. Empowered Funds LLC purchased a new stake in Sage Therapeutics in the fourth quarter valued at approximately $91,000. Ieq Capital LLC acquired a new stake in Sage Therapeutics during the 4th quarter worth approximately $57,000. US Bancorp DE lifted its holdings in Sage Therapeutics by 22.3% during the 4th quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company’s stock worth $67,000 after buying an additional 2,268 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Sage Therapeutics by 2.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 462,309 shares of the biopharmaceutical company’s stock valued at $2,510,000 after purchasing an additional 10,116 shares in the last quarter. 99.22% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have issued reports on SAGE. Scotiabank lowered their price objective on shares of Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating on the stock in a research report on Wednesday, February 12th. Bank of America started coverage on shares of Sage Therapeutics in a research report on Tuesday, March 11th. They issued an “underperform” rating and a $5.00 price objective for the company. HC Wainwright reaffirmed a “neutral” rating and set a $12.00 price target (down previously from $14.00) on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Wedbush restated a “neutral” rating and issued a $6.00 target price on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Sage Therapeutics in a research note on Friday, April 25th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.87.

Sage Therapeutics Trading Down 1.4%

NASDAQ:SAGE opened at $6.53 on Wednesday. Sage Therapeutics, Inc. has a twelve month low of $4.62 and a twelve month high of $13.47. The company has a 50-day moving average of $7.07 and a 200-day moving average of $6.77. The firm has a market cap of $408.92 million, a price-to-earnings ratio of -0.99 and a beta of 0.20.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. The business had revenue of $14.06 million for the quarter, compared to the consensus estimate of $14.12 million. During the same quarter last year, the business posted ($1.80) EPS. The business’s revenue for the quarter was up 78.0% on a year-over-year basis. On average, research analysts forecast that Sage Therapeutics, Inc. will post -3.52 earnings per share for the current year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.